Biogen Inc.: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025 · 2025 vs 2024
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
1
Removed
7
Modified
22
Unchanged
🔴 No Match in Current Filing The ongoing COVID-19 pandemic and other global health outbreaks may, directly or indirectly, adversely affect our business, results of operations and financial condition. 🔒
🟡 Modified A breakdown or breach of our information systems could subject us to liability or interrupt the operation of our business. 🔒
🟡 Modified Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives. 🔒
🟡 Modified We are substantially dependent on revenue from our products. 🔒
🟡 Modified Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury. 🔒
🟡 Modified Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts. 🔒
🟡 Modified The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges. 🔒
🟡 Modified We built a large-scale biologics manufacturing facility and are building a gene therapy manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped. 🔒
8 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →